RALEIGH, NC, January 8, 2014 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2014 at 4:30 p.m. PT (7:30 p.m. ET).
Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.
Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".
For more information, please visit our website at www.salix.com or contact Salix at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our filings with the U.S. Securities and Exchange Commission (the "SEC").
At Salix, we work hard every day to meet the current and anticipated needs of patients and healthcare providers. We are excited about the opportunity to drive this mission forward and are pleased to announce the successful completion of the acquisition of Santarus, Inc. We are looking forward to creating a new company with greater scope and impact than either company could offer independently. This is a transformational event for Salix and an important milestone in our growth as the leading company in gastrointestinal disease.